间断重复给予左西孟旦配合常规药物治疗终末期心力衰竭的效果及对血清NT-proBNP、NRG-1的影响  

Effect of Intermittent Repeated Administration of Levosimendan Combined with Conventional Drugs in the Treatment of End-stage Heart Failure and its Effect on Serum NT-proBNP and NRG-1

作　　者：熊俊 陈永洪 XIONG Jun;CHEN Yonghong(Department of Cardiology,Gucheng County People's Hospital,Gucheng 441700,Hubei,China)

机构地区：[1]谷城县人民医院心血管内科,湖北谷城441700

出　　处：《中国药物滥用防治杂志》2024年第10期1887-1890,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨间断重复给予左西孟旦配合常规药物对终末期心力衰竭的治疗效果。方法:纳入2020年4月—2022年6月谷城县人民医院诊治的84例终末期心力衰竭患者资料进行回顾性分析,以2020年4月—2021年5月接受常规药物治疗的43例患者为对照组,2021年6月—2022年6月间断重复给予左西孟旦配合常规药物治疗的41例患者为观察组,比较两组治疗后总体疗效,超声心动图参数、血清N末端-脑钠肽前体(NT-proBNP)、神经调节蛋白-1(NRG-1)水平及不良事件发生情况。结果:观察组治疗总有效率为82.93%,高于对照组的62.79%(P<0.05);观察组治疗后每搏输出量(SV)、左室射血分数(LVEF)、心输出量(CO)高于对照组(P<0.05);观察组治疗后血清NT-proBNP、NRG-1水平低于对照组(P<0.05);观察组随访期间非计划入院率、心源性死亡率低于对照组(P<0.05)。结论:间断重复给予左西孟旦配合常规药物治疗可提高终末期心力衰竭治疗效果,改善患者心功能,减少不良事件发生,并能下调血清NT-proBNP、NRG-1水平。Objective:To investigate the therapeutic effect of intermittent repeated administration of levosimendan combined with conventional drugs on end-stage heart failure.Methods:The data of 84 patients with end-stage heart failure diagnosed and treated in Gucheng County People's Hospital from April 2020 to June 2022 were retrospectively analyzed.Of 43 patients who received conventional drug treatment from April 2020 to May 2021 were used as the control group,41 patients who were given levosimendan intermittently and repeatedly combined with conventional drug treatment from June 2021 to June 2022 were used as the observation group.The overall efficacy,echocardiographic parameters,serum N-terminal-brain natriuretic peptide precursor(NT-proBNP),neuromodulin-1(NRG-1)levels and adverse events were compared between the two groups after treatment.Results:The total effective rate of treatment in the observation group was 82.93%,which was higher than 62.79%in the control group(P<0.05).After treatment,the stroke volume(SV),left ventricular ejection fraction(LVEF)and cardiac output(CO)in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of serum NT-proBNP and NRG-1 in the observation group were lower than those in the control group(P<0.05).The unplanned admission rate and cardiogenic mortality in the observation group were lower than those in the control group during the follow-up period(P<0.05).Conclusion:Intermittent repeated administration of levosimendan combined with conventional drug therapy can improve the therapeutic effect of end-stage heart failure,improve cardiac function,reduce adverse events,and down-regulate serum NT-proBNP and NRG-1 levels.

关 键 词：心力衰竭 左西孟旦 N末端-脑钠肽前体 神经调节蛋白-1 

分 类 号：R541.6[医药卫生—心血管疾病]